Payment overview · 2025
General Payments
$1,287.11
51 reported records · 15 companies
Healthcare provider profile · identity verified
Nina Kushner, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1104801091
Verified facts
What the public records show
CMS Open Payments records show Nina Kushner, MD received $1,287.11 in general payments during 2025 across 51 reported records.
ABBVIE INC. accounted for 32.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Gemtesa, Jardiance, Linzess, Nurtec Odt, Ozempic, Trelegy Ellipta, Trintellix, Ubrelvy, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 194 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ubrelvy by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 226 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 275 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nurtec Odt by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $416.63 | 32.4% | 18 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $216.90 | 16.9% | 8 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $131.48 | 10.2% | 5 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $112.79 | 8.8% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $111.41 | 8.7% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $71.72 | 5.6% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $34.02 | 2.6% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $32.29 | 2.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.92 | 2.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.91 | 2.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $24.19 | 1.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.82 | 1.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $19.77 | 1.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.80 | 1.5% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $18.46 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,287.11 | 51 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $268.83 | 12 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $246.80 | 10 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $156.63 | 6 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $112.79 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $106.18 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $64.67 | 3 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $60.27 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $59.48 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $51.89 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $51.22 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $34.02 | 1 | 2025 |
Source payment records
|
|||||
| ECC Solutions Normalized: ecc solutions |
Device | Philips North America LLC | $32.29 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $28.92 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $28.92 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $26.91 | 1 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $25.30 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.01 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $24.19 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.82 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.83 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $19.77 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.80 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $18.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 152 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 73 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 226 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 194 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 185 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 68 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 60 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 67 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
152 | 32 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
194 | 33 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
151 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
226 | 41 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
68 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
185 | 34 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
275 | 48 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
73 | 19 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 842 | 196 |
| Amlodipine Besylate | Amlodipine Besylate | 783 | 192 |
| Metoprolol Succinate | Metoprolol Succinate | 566 | 126 |
| Losartan Potassium | Losartan Potassium | 414 | 107 |
| Atorvastatin Calcium | Atorvastatin Calcium | 384 | 94 |
| Omeprazole | Omeprazole | 338 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 332 | 85 |
| Metformin Hcl Er | Metformin Hcl | 312 | 64 |
| Eliquis | Apixaban | 275 | 48 |
| Diclofenac Sodium | Diclofenac Sodium | 244 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 237 | 45 |
| Jardiance | Empagliflozin | 226 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 223 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 202 | 43 |
| Linzess | Linaclotide | 194 | 33 |
| Furosemide | Furosemide | 189 | 53 |
| Vascepa | Icosapent Ethyl | 189 | 28 |
| Ozempic | Semaglutide | 185 | 34 |
| Famotidine | Famotidine | 180 | 40 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 178 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 168 | 35 |
| Metformin Hcl | Metformin Hcl | 167 | 37 |
| Carvedilol | Carvedilol | 166 | 41 |
| Creon | Lipase/Protease/Amylase | 152 | 32 |
| Synthroid | Levothyroxine Sodium | 151 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 149 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 129 | 32 |
| Dexlansoprazole Dr | Dexlansoprazole | 126 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 39 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 119 | 21 |
| Simvastatin | Simvastatin | 117 | 25 |
| Gabapentin | Gabapentin | 114 | 29 |
| Mounjaro | Tirzepatide | 106 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 101 | 26 |
| Enalapril Maleate | Enalapril Maleate | 99 | 23 |
| Glimepiride | Glimepiride | 98 | 24 |
| Allopurinol | Allopurinol | 97 | 20 |
| Januvia | Sitagliptin Phosphate | 97 | 17 |
| Memantine Hcl Er | Memantine Hcl | 96 | 16 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 93 | 24 |
| Alendronate Sodium | Alendronate Sodium | 91 | 19 |
| Lisinopril | Lisinopril | 90 | 22 |
| Sertraline Hcl | Sertraline Hcl | 89 | 19 |
| Torsemide | Torsemide | 89 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 86 | 19 |
| Atenolol | Atenolol | 83 | 17 |
| Ketoconazole | Ketoconazole | 82 | 21 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 79 | 20 |
| Meloxicam | Meloxicam | 74 | 26 |
| Mupirocin | Mupirocin | 74 | 29 |
| Gemtesa | Vibegron | 73 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 71 | 33 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 70 | 14 |
| Trulicity | Dulaglutide | 70 | 12 |
| Lidocaine | Lidocaine | 69 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 16 |
| Potassium Chloride | Potassium Chloride | 67 | 21 |
| Zenpep | Lipase/Protease/Amylase | 67 | suppressed |
| Telmisartan | Telmisartan | 65 | 21 |
| Icosapent Ethyl | Icosapent Ethyl | 63 | 21 |
| Azithromycin | Azithromycin | 61 | 50 |
| Hydrocortisone | Hydrocortisone | 61 | 25 |
| Trintellix | Vortioxetine Hydrobromide | 60 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 59 | 15 |
| Metformin Er Gastric | Metformin Hcl | 59 | 11 |
| Clotrimazole | Clotrimazole | 57 | 21 |
| Alprazolam | Alprazolam | 56 | 20 |
| Xarelto | Rivaroxaban | 56 | suppressed |
| Chlorthalidone | Chlorthalidone | 55 | 15 |
| Clonazepam | Clonazepam | 55 | 16 |
| Single Use Swab | Alcohol Antiseptic Pads | 54 | 23 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 53 | 18 |
| Ezetimibe | Ezetimibe | 53 | 18 |
| Montelukast Sodium | Montelukast Sodium | 53 | 12 |
| Spironolactone | Spironolactone | 53 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 41 |
| Finasteride | Finasteride | 51 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 14 |
| Tradjenta | Linagliptin | 50 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 49 | suppressed |
| Nitroglycerin | Nitroglycerin | 49 | 19 |
| Azelastine Hcl | Azelastine Hcl | 48 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 46 | 14 |
| Benicar | Olmesartan Medoxomil | 46 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 46 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 46 | 20 |
| Tramadol Hcl | Tramadol Hcl | 46 | 13 |
| Valsartan | Valsartan | 46 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 46 | 11 |
| Farxiga | Dapagliflozin Propanediol | 44 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 44 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 44 | 12 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 42 | 28 |
| Doxazosin Mesylate | Doxazosin Mesylate | 42 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | 12 |
| Lorazepam | Lorazepam | 41 | 16 |
| Dexilant | Dexlansoprazole | 39 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 39 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 38 | suppressed |
| Ibuprofen | Ibuprofen | 38 | 20 |
| Valacyclovir | Valacyclovir Hcl | 38 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 37 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 36 | 20 |
| Repatha Sureclick | Evolocumab | 35 | suppressed |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 30 |
| Tresiba Flextouch U-200 | Insulin Degludec | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 31 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 31 | suppressed |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 28 | 12 |
| Glipizide Er | Glipizide | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Crestor | Rosuvastatin Calcium | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 14 |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Nystatin | Nystatin | 25 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 25 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Colchicine | Colchicine | 22 | 11 |
| Edarbi | Azilsartan Medoxomil | 22 | suppressed |
| Prolia | Denosumab | 22 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 15 |
| Ramipril | Ramipril | 20 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 18 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Cyclosporine | Cyclosporine | 17 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Eplerenone | Eplerenone | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Letrozole | Letrozole | 17 | suppressed |
| Prednisone | Prednisone | 17 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Ubrelvy | Ubrogepant | 16 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Lovaza | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Praluent Pen | Alirocumab | 14 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 13 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Terconazole | Terconazole | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Victoza 3-Pak | Liraglutide | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
| Uloric | Febuxostat | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
| Veo Insulin Syringe | Syrge-Ndl,ins 0.3 Ml Half Mark | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,287.11 · 51 records | ABBVIE INC. | ACCRUFER, AIRSUPRA, Auvelity, BREZTRI, CREON, ECC Solutions, GEMTESA, JARDIANCE, LINZESS, MYFEMBREE, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Symbravo, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VERQUVO, Wegovy, ZAVZPRET, ZENPEP, ZORYVE | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error